[go: up one dir, main page]

ES2089387T3 - Tratamiento de la hipertension ocular con la ayuda de una combinacion sinergica. - Google Patents

Tratamiento de la hipertension ocular con la ayuda de una combinacion sinergica.

Info

Publication number
ES2089387T3
ES2089387T3 ES92301412T ES92301412T ES2089387T3 ES 2089387 T3 ES2089387 T3 ES 2089387T3 ES 92301412 T ES92301412 T ES 92301412T ES 92301412 T ES92301412 T ES 92301412T ES 2089387 T3 ES2089387 T3 ES 2089387T3
Authority
ES
Spain
Prior art keywords
treatment
help
synergic combination
eye hypertension
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92301412T
Other languages
English (en)
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R Tech Ueno Ltd
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Application granted granted Critical
Publication of ES2089387T3 publication Critical patent/ES2089387T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UN METODO PARA EL TRATAMIENTO DE LA HIPERTENSION OCULAR QUE COMPRENDE LA ADMINISTRACION OCULAR, A UN SUJETO QUE NECESITA DICHO TRATAMIENTO, DE UN COMBINADO SINERGISTICO OCULO-HIPOTENSIBLE DE (A) UNA 5-ACETOPROSTAGLANDINA O DE UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, O UN ESTER FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, Y (B) UN INHIBIDOR DEL CARBONATO DE DEHIDRATASA EN UNA CANTIDAD EFECTIVA PARA EL TRATAMIENTO DE LA HIPERTENSION OCULAR.
ES92301412T 1991-03-01 1992-02-20 Tratamiento de la hipertension ocular con la ayuda de una combinacion sinergica. Expired - Lifetime ES2089387T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6132891 1991-03-01

Publications (1)

Publication Number Publication Date
ES2089387T3 true ES2089387T3 (es) 1996-10-01

Family

ID=13167964

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92301412T Expired - Lifetime ES2089387T3 (es) 1991-03-01 1992-02-20 Tratamiento de la hipertension ocular con la ayuda de una combinacion sinergica.

Country Status (11)

Country Link
US (1) US5547968A (es)
EP (1) EP0501678B1 (es)
JP (1) JP2511611B2 (es)
KR (1) KR100221369B1 (es)
AT (1) ATE137407T1 (es)
CA (1) CA2061907C (es)
DE (1) DE69210286T2 (es)
DK (1) DK0501678T3 (es)
ES (1) ES2089387T3 (es)
GR (1) GR3019820T3 (es)
TW (1) TW210287B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0948333A1 (en) * 1996-11-01 1999-10-13 Alcon Laboratories, Inc. Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
US7128903B2 (en) * 2001-10-03 2006-10-31 Innovative Pharmaceutical Concepts (Ipc) Inc. Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
WO2014010654A2 (ja) * 2012-07-13 2014-01-16 参天製薬株式会社 スルホンアミド化合物の組み合わせ
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0643313B2 (ja) * 1986-03-13 1994-06-08 ザ・トラステイ−ズ・オブ・コロンビア・ユニヴア−シテイ・イン・ザ・シテイ・オブ・ニユ−・ヨ−ク 緑内障の局所治療用組成物
ATE76750T1 (de) * 1987-04-03 1992-06-15 Univ Columbia Anwendung eines prostaglandins in mischung mit einem adrenergischen blocker zur verminderung des augen-innendruckes.
JPH0739343B2 (ja) * 1988-10-01 1995-05-01 株式会社アールテック・ウエノ 眼圧降下剤
ES2052735T3 (es) * 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
DE68928551T2 (de) * 1988-10-01 1998-04-23 Ueno Seiyaku Oyo Kenkyujo Kk Oculare hypotensive Mittel

Also Published As

Publication number Publication date
DE69210286T2 (de) 1996-09-12
CA2061907C (en) 2003-04-08
CA2061907A1 (en) 1992-09-02
EP0501678B1 (en) 1996-05-01
GR3019820T3 (en) 1996-08-31
TW210287B (es) 1993-08-01
DK0501678T3 (da) 1996-05-28
DE69210286D1 (de) 1996-06-05
KR920017654A (ko) 1992-10-21
EP0501678A2 (en) 1992-09-02
ATE137407T1 (de) 1996-05-15
JP2511611B2 (ja) 1996-07-03
US5547968A (en) 1996-08-20
JPH0565227A (ja) 1993-03-19
KR100221369B1 (ko) 1999-09-15
EP0501678A3 (en) 1992-12-16

Similar Documents

Publication Publication Date Title
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
ES2083030T3 (es) Metodo de tratamiento de la inflamacion ocular.
TW273550B (es)
PT97785A (pt) Metodo para a tratamento da impotencia utilizando, por exemplo, doxazosina
MY117109A (en) Injectable quinolone formulations.
MY114393A (en) 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1, 3-propanediol derivatives
UA41355C2 (uk) Засіб для лікування нейро-сніду
DK0458588T3 (da) Behandling af okulær hypertension med en synergistisk kombination til okulær administration
MX9706957A (es) Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina.
ES2089387T3 (es) Tratamiento de la hipertension ocular con la ayuda de una combinacion sinergica.
RU93058532A (ru) Фармацевтическая композиция для остеоиндукции, способ генерации новой кости
ES2069823T3 (es) Tratamiento de la hipertension ocular con una combinacion sinergica ocular.
ES2084771T3 (es) Tratamiento de la hipertension ocular con la ayuda de una combinacion sinergica.
ATE91419T1 (de) Synergistische kombination zur ophthalmischen verwendung.
DE69301387D1 (de) Behandlung des Glaukoms mit synergistischer Kombination
AU4228593A (en) Low level laser for soft tissue treatment
SE9403160D0 (sv) Method and means for prevention and treatment of secondary cataract
DE69331008D1 (de) Verwendung von cotinin zur linderung des tabakentzugssyndrom
MX9206135A (es) Metodos
NZ328198A (en) a pharmaceutical composition containing hydroxyzine and a serotonin uptake inhibitor
DK0711163T3 (da) Anvendelse af benzydamin i behandlingen af patologiske tilstande forårsaget af TNF
MY118982A (en) Method of reducing tissue damage associated with ischemia
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
EE200100122A (et) R-(+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli kasutamine unehäirete raviks
DE69626307D1 (de) Inhibitor von stickstoffmonoxid (no) synthase zur verhütung von typ ii diabetes

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 501678

Country of ref document: ES

FG2A Definitive protection

Ref document number: 501678

Country of ref document: ES